Smoking is a major concern for patients diagnosed with cancer and those who have survived cancer. Research, including more than 400 studies reviewed in the 2014 Surgeon General’s report, has consistently shown that smoking after a cancer diagnosis significantly increases both general and cancer-specific mortality. Patients who continue to smoke face a 50% higher risk of overall mortality and a 61% higher risk of cancer-related mortality. These alarming statistics underscore the urgent need for effective smoking cessation strategies integrated into cancer care.

Key Findings on Smoking Cessation

A recent study underscores the vital importance of early smoking cessation for patients diagnosed with cancer. The research shows that quitting smoking within six months of a cancer diagnosis dramatically improves survival rates. Specifically, the adjusted hazard ratios for those who stopped smoking are 0.75 at three months, 0.79 at six months, and 0.85 at nine months. For abstainers, survival at the 75th percentile increases from 2.1 years to 3.9 years, highlighting substantial benefits. This demonstrates the life-extending impact of quitting smoking shortly after diagnosis. One patient noted, “If you can get a 20-year-old to stop smoking today, then by the time they are 60-, 65-years-old they are going to be pretty darn physically and mentally fit compared to somebody like myself with a litany of cigarette induced illnesses” (Canadian Partnership Against Cancer).

The Role of the Tobacco Research and Treatment Program

The Tobacco Research and Treatment Program (TRTP) at the University of Texas MD Anderson Cancer Center has been at the forefront of providing structured smoking cessation interventions since 2006. Supported by the State of Texas Tobacco Settlement Funds, the programme offers free, evidence-based treatment for patients seeking to quit smoking. The interventions are tailored to each individual, comprising cognitive behavioural counselling, motivational interviewing, and pharmacotherapy. Medications such as nicotine replacement therapy, bupropion, and varenicline are used, either singly or in combination. Notably, more than 95% of these interventions are delivered via telemedicine, ensuring accessibility and convenience for patients.

Integrating Smoking Cessation into Cancer Care

Despite the clear benefits of quitting smoking, many oncology clinicians do not routinely assist patients in smoking cessation. This gap in care highlights the need for smoking cessation to become a standard component of cancer treatment. By incorporating structured cessation programmes at the time of diagnosis, healthcare providers can improve life expectancy and enhance the effectiveness of cancer treatments.

Implications for Cancer Patients

The study’s compelling evidence suggests that early intervention in smoking cessation can mitigate the mortality risks associated with smoking, even within the initial years following diagnosis. Therefore, prioritising tobacco cessation should be a core element of first-line cancer care. Large cancer organisations are urged to make such programmes a standard part of treatment to maximise patient outcomes and support better overall health.

Incorporating smoking cessation into cancer care is essential for improving survival and quality of life. Overall, this research emphasises the critical need to offer structured smoking cessation programmes as an integral part of cancer care. By doing so, we can significantly improve the survival and quality of life for patients confronting the dual challenges of cancer and smoking.

Source: Jama Network